Aehr Test Systems Multiples Expand to 18.59x Forward Sales on $100.6M AI Test Backlog
Resolved · valuation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-22. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Multiple expansion to 18.59x forward sales leaves AEHR equity vulnerable to valuation compression if $100.6M backlog conversion slows.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factAehr Test Systems (AEHR) stock has gained 363% year-to-date in 2026, driven by demand for AI semiconductor test equipment. |
| What else was confirmed? | Reported factThe equity currently trades at a forward price-to-sales multiple of 18.59x, which is more than three times its historical median multiple. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for AEHR; the latest is dated 2026-07-14. |
| What would change the assessment? | UnknownAEHR Backlog Conversion and Order Inflow — Monitor new burn-in order announcements relative to the existing $100.6M backlog baseline. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Aehr Test Systems (AEHR) stock has gained 363% year-to-date in 2026, driven by demand for AI semiconductor test equipment.
- · The equity currently trades at a forward price-to-sales multiple of 18.59x, which is more than three times its historical median multiple.
- · The company maintains an active order backlog of $100.6 million.
Public research record
Research framework · page evidenceCompleted event assessment
forward multiple compression risk against equipment backlog execution
| Type | Claim | Scope |
|---|---|---|
| Assumption | Aehr Test Systems (AEHR) stock has gained 363% year-to-date in 2026, driven by demand for AI semiconductor test equipment. | 2026-09-22 |
| Interpretation | forward multiple compression risk against equipment backlog execution | AEHR |
Countercase, invalidators, and sources
Rapid conversion of $100.6M backlog into revenue supports high sales multiple.
- · AEHR Backlog Conversion and Order Inflow — Monitor new burn-in order announcements relative to the existing $100.6M backlog baseline.
- AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind? · 2026-09-21
What remains unresolved
- Base path
- Stock trades in a high-volatility consolidation range near 18.5x sales as orders are recognized.
- Adverse path
- Customer acceptance delays trigger multiple compression toward historical single-digit sales levels.
- Supportive path
- Rapid conversion of $100.6M backlog into revenue supports high sales multiple.
- · AEHR Backlog Conversion and Order Inflow — Monitor new burn-in order announcements relative to the existing $100.6M backlog baseline.this week
Evidence
- AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind?2026-09-21
“Aehr Test Systems (AEHR) has surged 363% in 2026 driven by AI semiconductor testing demand, but now trades at 18.59X forward sales - over 3x its historical median. While the company has strong backlog ($100.6M) and positive analyst sentiment, the elevated valuation leaves minimal margin for error.”
Supports: AEHR gained 363% in 2026, trades at 18.59x forward sales (>3x historical median), with a $100.6M backlog.